Zai Lab Limited
基本情報
- 所在地
- Building B, 899 Halei Road Pudong, 201203 China
- 社長
- Ying Du
- 従業員数(単独)
- 1,784 人
- 従業員数(連結)
- 開始日
- 2013-01-01
- 終了日
サイト
事業内容
関連会社
| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
| GE Healthcare | ||||||||
| MediLink Therapeutics | ||||||||
| innovaTV |
関連図
沿革
In the second quarter of 2017, Zai Lab initiated a Phase II trial of ZL-2301 as a second-line treatment for advanced hepatocellular cancer patients in China.
Zai Lab initiated a Phase II study of ZL-3101 in eczema patients in China during the second quarter of 2017.
In April 2017, Zai Lab in-licensed exclusive regional rights to ZL-2401, a broad spectrum antibiotic, from Paratek Pharmaceuticals.
In September 2017, Zai Lab dosed the first patient in its Phase 3 China registration trial of ZL-2306 as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
In November 2017, Zai Lab initiated a pharmacokinetic (PK) study to establish the PK profile of ZL-2306 in Chinese patients.
In December 2017, Zai Lab in-licensed exclusive regional rights to FPA 144 from Five Prime Therapeutics.
In the US, an NDA was submitted for ZL-2401 in February 2018.
Zai Lab entered in to an exclusive licensing agreement and collaboration with Entasis Therapeutics for ETX2514 on April 25, 2018.
On August 8, 2018, Antimicrobials Drug Advisory Committee of the U.S. FDA voted in favor of the approval of IV and oral omadacycline.
ニュース
ニュースはありません。